|
||
| |||||||
|
Cobra Biomanufacturing appoints Cathy Smith to strengthen North America Sales Keele,
UK, September 30th 2004
– Cobra Biomanufacturing Plc (London Stock Exchange AIM) has appointed Cathy
Smith to the new role of Vice President, Business Development. Cathy joins Cobra
from her most recent position as Sales Manager at Cambrex Biopharmaceuticals,
Baltimore, MD and Hopkinton, MA and brings over 5 years of sales, marketing and
business development experience. She is based in San Francisco, California and
will be responsible for further positioning Cobra as a leading manufacturer of
biopharmaceuticals on the West Coast of USA. “We are delighted that an individual of Cathy’s calibre has joined Cobra. I anticipate that she will make a valuable contribution in our drive to expand our North American customer base. Importantly, our North American customers will benefit from her wealth of experience in biomanufacturing,” commented Dr David Thatcher, CEO, Cobra. Cathy has worked in the USA for several leading international biotechnology companies. Most recently at Cambrex Biopharmaceuticals she received the Cambrex Biopharmaceuticals Outstanding Sales Achievement Award in 2002. Previous to Cambrex, she was at Chiron Corporation, Emeryville, California as a Manager of Manufacturing Business Development. Prior to Chiron, Cathy held positions at Berlex Biosciences of Richmond, California (a wholly owned subsidiary of Schering AG, Germany). Commenting on her appointment at Cobra, Cathy said: “I am delighted to join Cobra as part of their sales team at an exciting time in the Company’s expansion. Cobra has recently increased its recombinant protein cGMP manufacturing capabilities to better serve the North American market by opening a new world class facility in Oxford, UK. I particularly admire Cobra’s innovative approaches that develop optimal solutions for each stage of the biomanufacturing process.” -Ends- For
further information please contact:
About
Cobra Biomanufacturing Plc Cobra
Biomanufacturing Plc is a leading international manufacturer of
biopharmaceuticals to the life science industry. Founded in 1992, Cobra provides
innovative manufacturing solutions to the biopharmaceutical industry covering
DNA, virus, cellular therapeutics and recombinant protein products. Cobra was
the first company to develop GMP (Good Manufacturing Practice) standard DNA
manufacture in Europe, with specific expertise in DNA medicines. Cobra
floated on the Alternative Investment Market of the London Stock Exchange in
June 2002 raising £7 million and raised a further £5.2 million in May 2003 in
order to further expand capacity in Oxford UK |
|
| ||||||||